Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03835533 |
Recruitment Status :
Recruiting
First Posted : February 8, 2019
Last Update Posted : December 8, 2020
|
Sponsor:
Parker Institute for Cancer Immunotherapy
Collaborators:
Bristol-Myers Squibb
Celldex Therapeutics
Cancer Research Institute, New York City
Inovio Pharmaceuticals
Oncovir, Inc.
Information provided by (Responsible Party):
Parker Institute for Cancer Immunotherapy
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | March 2022 |
Estimated Study Completion Date : | March 2023 |
Publications: